11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

Pediatric endocrinology encompasses complex hormonal axes that govern linear growth, sexual maturation, and fluid-electrolyte homeostasis. Pharmacotherapy in these conditions requires precise developmental dosing calculations, careful mitigation of growth-stunting drug toxicities, and rapid emergency intervention during acute adrenal decompensation.

---

Recombinant Human Growth Hormone (Somatropin)

Somatropin is produced by recombinant DNA technology and has an identical 191-amino acid sequence to endogenous pituitary human growth hormone. It stimulates linear bone growth at the epiphyseal growth plates primarily through hepatic and peripheral production of Insulin-like Growth Factor 1 (IGF-1), while exerting direct anabolic effects on skeletal muscle and lipolytic effects on adipose tissue.

Somatropin Clinical Indications & Pediatric Dosing Spectrum:

┌─────────────────────────────┬───────────────────────────┬───────────────────────────────────────┐
│ Pediatric Indication        │ Dosing (mg/kg/week)       │ Clinical Context & Monitoring Pearls  │
├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
│ Growth Hormone Deficiency   │ 0.16 to 0.24 mg/kg/week   │ Peak GH <10 ng/mL on 2 stim tests;    │
│ (GHD)                       │ (0.024–0.034 mg/kg/day)   │ highly responsive to lower doses      │
├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
│ Turner Syndrome (45,XO)     │ 0.35 to 0.375 mg/kg/week  │ SHOX haploinsufficiency; relative GH  │
│                             │ (up to 0.05 mg/kg/day)    │ resistance; initiate at age 2–4 yr    │
├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
│ Small for Gestational Age   │ 0.35 to 0.48 mg/kg/week   │ Birth wt/length <-2 SD failing catch- │
│ (SGA failing catch-up)      │ (0.05–0.07 mg/kg/day)     │ up growth by chronological age 2–4 yr │
├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
│ Chronic Kidney Disease      │ 0.35 mg/kg/week           │ Uremic GH resistance; administer      │
│ (CKD prior to transplant)   │ (~0.05 mg/kg/day)         │ until renal transplantation occurs    │
├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
│ Prader-Willi Syndrome (PWS) │ 0.24 mg/kg/week           │ Screen for sleep apnea/airway obstruc-│
│                             │ (or 1.0 mg/m2/day)        │ tion before initiation (sudden death) │
└─────────────────────────────┴───────────────────────────┴───────────────────────────────────────┘

Administration & Therapeutic Drug Monitoring

• Route & Timing: Administered via daily subcutaneous injections in the evening. Evening dosing mimics the natural physiological nocturnal secretion of growth hormone that occurs during slow-wave deep sleep.
• Serum IGF-1 & IGFBP-3 Monitoring: Serum IGF-1 concentrations should be monitored every 6 to 12 months and maintained within the normal age- and sex-adjusted reference range (-1 to +2 standard deviation scores [SDS]). Elevated IGF-1 levels (> +2 SDS) mandate dose reduction to prevent acromegalic bone changes and metabolic complications.
• Endocrine & Safety Labs:
  • Thyroid Function: Growth hormone accelerates the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), which may unmask underlying central hypothyroidism. Free T4 and TSH should be checked at baseline and every 6 to 12 months.
  • Glucose Homeostasis: Somatropin antagonizes insulin signaling and stimulates hepatic gluconeogenesis; fasting glucose and HbA1c should be tracked in children with obesity or family risk of diabetes.

Adverse Effects & Critical Clinical Traps

1. Benign Intracranial Hypertension (Pseudotumor Cerebri): Typically presents within the first 8 to 12 weeks of initiation with severe morning headaches, nausea, vomiting, diplopia, and bilateral papilledema on fundoscopy. Somatropin must be discontinued immediately. Symptoms typically resolve within days to weeks; therapy may be cautiously re-introduced at a lower dose after complete ophthalmological resolution.
2. Slipped Capital Femoral Epiphysis (SCFE): Rapid linear growth places mechanical shear stress across the proximal femoral physis, causing posterior and medial displacement of the femoral head. Children present with hip, groin, or referred knee/thigh pain and an antalgic limp. Requires immediate non-weight bearing status and emergent orthopedic surgical evaluation for percutaneous in situ screw pinning.
3. Progression of Scoliosis: Rapid spinal growth can exacerbate preexisting scoliosis curves; spine surveillance is mandatory.
4. Prader-Willi Syndrome Airway Mortality: Recombinant GH can induce tonsillar hypertrophy and adenoidal enlargement. A formal polysomnography (sleep study) is mandatory prior to initiation to rule out severe upper airway obstruction; somatropin is contraindicated in severely obese PWS patients or those with severe respiratory impairment.

---

Congenital Adrenal Hyperplasia (CAH)

Congenital Adrenal Hyperplasia comprises a group of autosomal recessive disorders of adrenal steroidogenesis. Over 90% to 95% of cases are caused by mutations in the CYP21A2 gene encoding the 21-hydroxylase cytochrome P450 enzyme located on chromosome 6p21.3.

Adrenal Steroidogenic Pathway in 21-Hydroxylase Deficiency (CAH):

                 Cholesterol
                      │
                      ▼
                 Pregnenolone ─────────────────► 17-OH Pregnenolone ────────► DHEA
                      │                                │                         │
                      ▼                                ▼                         ▼
                 Progesterone ─────────────────► 17-OHP                  Androstenedione
                      │                                │                         │
          21-OHase ───X (BLOCKED!)         21-OHase ───X (BLOCKED!)              ▼
                      ▼                                ▼                    TESTOSTERONE
             11-Deoxycorticosterone          11-Deoxycortisol                    │
                      │                                │                         ▼
                      ▼                                ▼                 VIRILIZATION IN UTERO
                 ALDOSTERONE                       CORTISOL              (Ambiguous Genitalia
                      │                                │                   in 46,XX Females)
                      ▼                                ▼
           SALT-WASTING CRISIS              LOSS OF NEGATIVE FEEDBACK
          (Hyponatremia, Shock,              ON PITUITARY ──► MASSIVE
              Hyperkalemia)                   ACTH OVERPRODUCTION

Pathophysiologic Consequences of 21-Hydroxylase Deficiency

1. Cortisol Deficiency & Pituitary Overactivation: Deficient cortisol synthesis eliminates normal negative feedback on the hypothalamus and anterior pituitary. The pituitary hypersecretes Adrenocorticotropic Hormone (ACTH), which drives continuous hyperplasia of the adrenal cortex.
2. Steroid Precursor Accumulation & Androgen Shunting: The enzymatic block causes massive accumulation of upstream precursors, particularly 17-hydroxyprogesterone (17-OHP) and progesterone. These precursors are shunted into intact adrenal androgen synthesis pathways, generating massive excess of androstenedione and testosterone.
3. Aldosterone Deficiency: Complete or near-complete lack of 21-hydroxylase impairs mineralocorticoid production, causing renal sodium and water wasting, hypovolemia, and potassium retention.

Clinical Phenotypes & The Neonatal Salt-Wasting Crisis

• Classic Salt-Wasting (SW) CAH (~75% of classic cases): Severe enzyme deficiency (<1% activity). Cortisol AND aldosterone are deficient.
  • In 46,XX Genetic Females: Exposed to massive androgen concentrations in utero, presenting at birth with ambiguous external genitalia (clitoral hypertrophy, labial fusion forming a scrotum-like structure, single urogenital sinus; Prader stages 1–5). Internal reproductive anatomy (uterus, fallopian tubes, ovaries) is completely normal.
  • In 46,XY Genetic Males: Genitalia appear normal at birth (sometimes subtle scrotal hyperpigmentation). Consequently, affected males escape neonatal visual detection and present between days 7 and 14 of life with life-threatening adrenal salt-wasting crisis.
• Triad of Acute Salt-Wasting Crisis:
  • Severe hyponatremia (serum Na < 120–125 mEq/L)
  • Severe hyperkalemia (serum K > 7.0–8.5 mEq/L with peaked T waves and ventricular arrhythmias)
  • Hypovolemic shock, dehydration (>10% weight loss from birth), and metabolic acidosis
  • Frequent hypoglycemia (loss of cortisol counterregulation)
  • Clinical Trap: Frequently misdiagnosed as septic shock, pyloric stenosis, or congenital cardiac failure.
• Diagnostic Confirmation: Newborn dried blood-spot screening demonstrates markedly elevated 17-hydroxyprogesterone (17-OHP) levels (often > 10,000 ng/dL vs. normal < 100–200 ng/dL), confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

---

Pharmacotherapy of Classic CAH

Pharmacotherapeutic Regimen for Classic Congenital Adrenal Hyperplasia:

1. GLUCOCORTICOID REPLACEMENT:
   • Drug of Choice: ORAL HYDROCORTISONE (Cortisol)
   • Dose: 8 to 15 mg/m2/day divided THREE TIMES DAILY (TID)
   • Why Hydrocortisone? Short tissue half-life (1.5-2 hr) prevents irreversible growth stunting
   • Avoid Dexamethasone & Prednisone in growing children! (Causes severe growth suppression)
   • Monitoring: Titrated to normalize 17-OHP, androstenedione, and linear growth velocity

2. MINERALOCORTICOID REPLACEMENT:
   • Drug: FLUDROCORTISONE ACETATE (Florinef)
   • Dose: 0.05 to 0.2 mg orally once daily (or divided BID in neonates)
   • Normalizes blood pressure, serum sodium, and suppresses plasma renin activity (PRA)

3. SODIUM CHLORIDE SUPPLEMENTATION (Infancy):
   • Dose: Oral NaCl 1 to 2 g/day (~17 to 34 mEq/day) divided with breast milk / formula feedings
   • Essential during first 12 months because infant diet has low sodium & infant kidneys resist aldosterone

4. STRESS-DOSING RULES (Illness / Surgery):
   • Fever (>38.5°C) or moderate illness: DOUBLE or TRIPLE oral hydrocortisone (30-50 mg/m2/day)
   • Emesis, shock, surgery, NPO: Emergency PARENTERAL SOLU-CORTEF IM/IV immediately:
     - Age <3 years: 25 mg IM/IV bolus
     - Age 3-12 years: 50 mg IM/IV bolus
     - Age >12 years: 100 mg IM/IV bolus

Why Hydrocortisone is the Exclusive Glucocorticoid of Choice

• In pediatric patients with open epiphyses, oral hydrocortisone is the standard of care. It has low glucocorticoid potency (1.0 vs 4.0 for prednisone and 30.0 for dexamethasone) and a short biologic half-life (8 to 12 hours). This short duration minimizes nocturnal suppression of growth hormone release.
• Prednisone and Dexamethasone Danger: Synthetic long-acting glucocorticoids have prolonged tissue residence times that cause profound hypothalamic-pituitary suppression, severe linear growth stunting, Cushingoid facies, truncal obesity, osteopenia, and significantly reduced adult height. They are strictly reserved for post-pubertal adolescents who have attained final adult height.

Stress-Dosing Protocols to Prevent Fatal Adrenal Crisis

During systemic illness, fever, or physical trauma, normal physiological cortisol production surges 3- to 5-fold. Children with CAH cannot mount this response:

• Mild-to-Moderate Illness (Fever > 38.5°C, gastroenteritis without vomiting): Double or triple the baseline oral hydrocortisone dose (30 to 50 mg/m2/day divided TID or QID). Fludrocortisone dosing remains unchanged.
• Severe Stress, Persistent Emesis, Trauma, or General Anesthesia: Families and emergency personnel must immediately administer intramuscular Hydrocortisone sodium succinate (Solu-Cortef) at age-stratified doses (25 mg for <3 yr; 50 mg for 3–12 yr; 100 mg for ≥12 yr) and initiate emergency transport. Intravenous maintenance fluids containing 5% Dextrose in 0.9% Normal Saline (D5 0.9% NaCl) must be infused to correct hypoglycemia and hypovolemia.

---

Central Precocious Puberty (CPP)

Central Precocious Puberty (CPP, gonadotropin-dependent precocious puberty) is caused by premature, early reactivation of the hypothalamic pulsatile gonadotropin-releasing hormone (GnRH) pulse generator.

• Diagnostic Thresholds: Appearance of secondary sexual characteristics before age 8 years in girls (breast bud development [thelarche] or pubarche) and before age 9 years in boys (bilateral testicular enlargement ≥ 4 mL [measured via Prader orchidometer] or pubarche).
• Consequences: Premature production of sex steroids (estradiol or testosterone) drives rapid somatic growth velocity accompanied by accelerated skeletal maturation. This causes premature epiphyseal plate fusion, resulting in severe reduction in final adult height (frequently < 5 feet tall), alongside significant psychosocial distress.

Mechanism of GnRH Receptor Down-Regulation by GnRH Agonists in CPP:

Physiological State: Pulsatile GnRH Secretion (Every 60-90 min)
┌─────────────────────────────────────────────────────────────────────────────┐
│ Hypothalamus ──► Pulsatile GnRH ──► Pituitary GnRH Receptors ──► LH & FSH   │
│ (Promotes normal receptor recycling & continuous pubertal sex steroid surge)│
└─────────────────────────────────────────────────────────────────────────────┘
                                       │
                                       ▼ Continuous Agonist Infusion
Therapeutic State: Continuous GnRH Agonist Therapy (Leuprolide, Histrelin)
┌─────────────────────────────────────────────────────────────────────────────┐
│ Initial Phase (Days 1–14): Transient "Flare" of LH, FSH, and Sex Steroids   │
│                                      │                                      │
│ Chronic Phase (> 2–4 Weeks): RECEPTOR INTERNALIZATION & DESENSITIZATION     │
│ • Pituitary uncoupling of G-protein signaling                               │
│ • Profound suppression of LH (< 0.3–0.5 IU/L) and FSH                       │
│ • Estradiol (< 10 pg/mL) & Testosterone (< 30 ng/dL) drop to prepubertal    │
│ • Linear growth velocity normalizes (4–6 cm/yr); bone age maturation stops  │
│ • Preserves and optimizes final adult height                                │
└─────────────────────────────────────────────────────────────────────────────┘

Pharmacotherapy with GnRH Agonists

Monitoring & Discontinuation Criteria

• Suppression Verification: Clinical efficacy is confirmed by measuring GnRH-stimulated peak LH levels (suppressed to < 0.3 to 0.5 IU/L), prepubertal estradiol (< 10 pg/mL in girls), and prepubertal testosterone (< 30 ng/dL in boys).
• Skeletal & Growth Surveillance: Height velocity should decelerate to normal prepubertal rates (4 to 6 cm/year), and bone age progression should stabilize relative to chronological age on annual hand/wrist radiographs.
• Discontinuation Timing: Therapy is electively discontinued when the child reaches the chronologically appropriate age for normal puberty (typically age 11 years in girls and age 12 years in boys, or when bone age reaches ~12 to 12.5 years in girls and 13 to 13.5 years in boys). Normal hypothalamic-pituitary-gonadal axis pulsatility resumes within 6 to 12 months after drug cessation, culminating in normal spontaneous puberty, menarche, and future reproductive fertility.